Ulcerative Colitis

Compared with placebo, most biologic and small molecule therapies correlated with superiority for the induction of remission in moderate to severe ulcerative colitis, according to research published in Gut.

Among patients with inflammatory bowel disease, the effectiveness of the COVID-19 vaccine was similar when compared to controls without the disease, according to study results.

Early anti-tumor necrosis factor administration reduced late B2 development among pediatric patients with Crohn’s disease, according to a presenter.

A point-of-care intestinal ultrasound effectively assessed endoscopic disease severity through bowel wall thickness, according to a poster presentation.

Oral lyophilized fecal microbiota transplantation following antibiotic use induced and maintained remission in patients with active ulcerative colitis, according to research published in Lancet Gastroenterology and Hepatology.

In a video exclusive, Jan Wehkamp, MD, vice president, gastroenterology global disease area leader at Janssen Pharmaceuticals, reported positive long-term data evaluating Tremfya for the treatment of patients with Crohn’s disease.

Immunocompromised individuals have several justifiable concerns surrounding COVID-19. One of those concerns is that a two-dose vaccine schedule may not produce a sufficient antibody response to protect them from the virus.

Using a novel clinical pathway integrated into the electronic medical record, researchers were able to identify patients with inflammatory bowel disease who were overdue for medical follow-ups, according to data presented at the ACG Annual Scientific Meeting.

In a commentary published in Gastroenterology, experts propose initiatives that aim to increase diversity in inflammatory bowel disease clinical trials.

Among patients with inflammatory bowel disease who received at least two biologic therapies, discontinuation of treatment appeared to vary based on initial treatment choice, according to data presented at the ACG Annual Scientific Meeting.